Introduction
============

Bladder cancer is one of the most common types of cancer worldwide and was the most common urological tumor in China in 2012 ([@b1-ol-0-0-7310]). In 2012, of the individuals with bladder cancer, 90% were diagnosed at \>65 years-of-age worldwide ([@b2-ol-0-0-7310]). This disease is a common malignancy characterized by a poor clinical outcome ([@b3-ol-0-0-7310]); therefore, investigations into the underlying molecular mechanisms are urgently required in order to facilitate improvements in early diagnosis and treatments.

Bladder cancer is considered a genetic disease and is driven by the multistep accumulation of genetic and epigenetic factors that usually result in uncontrolled cellular proliferation, cell cycle deregulation or a decrease in cell death ([@b3-ol-0-0-7310]). The two different types of genetic alterations that are observed in bladder cancer are tumor protein p53 mutations and a number of single-nucleotide and structural variants, as well as chromosome shattering ([@b4-ol-0-0-7310]). Di Pierro *et al* ([@b1-ol-0-0-7310]) revealed that mutations in *FGFR3* and *TP53* are usually predictive of bladder malignancy. Overexpression of PIN2/TRF1-interacting telomerase inhibitor 1 in urothelial carcinoma of the bladder inhibited cell proliferation by inhibiting telomerase activity and the p16/cyclin D1 signaling pathway ([@b5-ol-0-0-7310]). Furthermore, chromosomal instability (CIN) characterized by loss or gain of chromosomal fragments or entire chromosomes is most prevalent in invasive urothelial cancer, compared with other less malignant papillary subtypes ([@b6-ol-0-0-7310]). Checkpoint dysfunction serves an important role in the development of CIN and is caused by defects in cell cycle regulation, p53 function and checkpoint signaling ([@b7-ol-0-0-7310]). Although certain studies have reported that gene mutations, telomerase activity and chromosomal instability are connected with bladder cancer ([@b4-ol-0-0-7310]--[@b7-ol-0-0-7310]), the exact molecular mechanism of bladder cancer remains unclear. A profound understanding of the molecular mechanism of action may be useful to provide an improved, more efficient handling of bladder cancer.

In the present study, the raw microarray data GSE52519 were downloaded to investigate the underlying molecular mechanisms of bladder cancer. Gene Ontology-Biological Process (GO-BP) functional analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Reactome pathway enrichment analysis were performed for down- and upregulated differentially expressed genes (DEGs). Subsequently, transcription factors and genes associated with cancer for DEGs were identified. In addition, a protein-protein interaction (PPI) network and its core sub-network were constructed, and KEGG pathway enrichment analysis of the genes in the identified core PPI sub-network was also performed.

Materials and methods
=====================

### Microarray data and data preprocessing

The raw microarray data GSE52519 were downloaded from Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52519](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE52519)). GSE52519 comprises 9 bladder cancer tissue samples obtained during cystectomy and 3 normal tissue samples derived from post mortem donors without bladder cancer. The microarray platform of GSE52519 was GPL13497 Illumina HumanWG-6 v3.0 Expression BeadChip (Illumina, Inc., San Diego, CA, USA).

The gene expression profile was preprocessed using Limma (version 3.83; linear models for microarray data; [www.bioconductor.org/packages/2.8/bioc/html/limma.html](www.bioconductor.org/packages/2.8/bioc/html/limma.html)) package in Bioconductor ([@b8-ol-0-0-7310]) and Affymetrix annotation files from Brain Array Lab (version 20; <http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF_download.asp>) ([@b9-ol-0-0-7310]). The background correction, quantile normalization and probe summarization of the microarray data were performed using the Robust Multi-Array Average algorithm ([@b10-ol-0-0-7310]) to obtain the gene expression matrix.

### Identification of DEGs

The normalized data were calculated with the Limma package ([@b8-ol-0-0-7310]), and genes with P\<0.01 and \|log~2~fold change\|≥2 were considered to indicate a statistically significant difference between the bladder cancer group and the normal group.

### Enrichment analysis of DEGs

The Database for Annotation, Visualization and Integrated Discovery (DAVID; [david.abcc.ncifcrf.gov](david.abcc.ncifcrf.gov)) is a comprehensive functional annotation tool ([@b10-ol-0-0-7310],[@b11-ol-0-0-7310]). Based on DAVID online analysis, GO-BP functional enrichment analysis was performed for DEGs ([@b12-ol-0-0-7310]); P\<0.01 was selected as the threshold criterion.

KEGG is a knowledge base for systematic analysis of gene functions, and the PATHWAR database ([www.kegg.jp/kegg/pathway.html](www.kegg.jp/kegg/pathway.html)) is supplemented by the information of conserved sub-pathways ([@b13-ol-0-0-7310]). The Reactome database ([www.reactome.org](www.reactome.org)) is an open-source open-data resource of human pathways and reactions ([@b14-ol-0-0-7310]). Pathway enrichment analysis was performed for the DEGs using these two databases, with the threshold of P\<0.01.

### Identification of transcription factors and genes associated with cancer from DEGs

Transcription factor analysis using the TRANSFAC database ([www.biobase-international.com/product/transcription-factor-binding-sites\#resources](www.biobase-international.com/product/transcription-factor-binding-sites#resources)) ([@b15-ol-0-0-7310]) was performed on DEGs to determine whether the genes were transcription factors. The DEGs were also submitted to the Tumor Suppressor Gene database ([bioinfo.mc.vanderbilt.edu/TSGene](bioinfo.mc.vanderbilt.edu/TSGene)) ([@b16-ol-0-0-7310]) and the Tumor-Associated Gene database ([blog.synopse.info/tag/Database](blog.synopse.info/tag/Database)) ([@b17-ol-0-0-7310]) to obtain all known proto-oncogenes and tumor suppressor genes.

### Construction of PPI network and PPI sub-network analysis

DEGs were submitted to STRING version 9.1 (Search Tool for the Retrieval of Interacting Genes; [string.embl.de](string.embl.de)) ([@b18-ol-0-0-7310]) to search interaction associations of the proteins; the confidence score \>0.9 was used as the threshold criterion. Then, visualization of the PPI network was performed using Cytoscape software ([cytoscape.org](cytoscape.org)) ([@b19-ol-0-0-7310]). The HUB nodes with the top 5 degrees in the PPI network were also obtained.

The PPI sub-network of DEGs was identified by BioNet ([@b20-ol-0-0-7310]), and a false discovery rate of \<0.01 was selected as the threshold criterion. The pathway enrichment analysis of genes in the core PPI sub-network was performed using the KEGG database, and P\<0.01 was selected as the threshold criterion.

Results
=======

### DEG analysis

A total of 779 transcripts and 755 DEGs were identified in the bladder cancer and the normal group combined, including 431 downregulated transcripts that corresponded to 420 downregulated DEGs, and 348 upregulated transcripts that corresponded to 335 upregulated DEGs.

### Enrichment analysis of DEGs

The top three enriched GO terms in the BP category of downregulated DEGs included muscle contraction (P=3.60×10^−5^), involving DEGs such as *CRYAB, TACR2* and *MYH3*, muscle system process (P=9.48×10^−5^) associated with DEGs such as *CRYAB, TACR2* and *MYH3*, and actin filament-based process (P=3.19×10^−4^) involving DEGs such as *DLC1, MYH3* and *CALD1* ([Table I](#tI-ol-0-0-7310){ref-type="table"}). The only two enriched KEGG pathways of downregulated DEGs included focal adhesion (P=3.86×10^−3^; e.g., *PRKCA, LAMA3* and *ITGA8*) and tight junction (P=8.10×10^−3^; e.g., *PRKCA, GNAI1* and *MYH3*) ([Table II](#tII-ol-0-0-7310){ref-type="table"}). Additionally, five downregulated DEGs (*TNNT3, DES, MYH3, DMD* and *TPM2*) were significantly enriched in the Reactome pathway of muscle contraction (P=2.46×10^−3^; [Table III](#tIII-ol-0-0-7310){ref-type="table"}).

The top three enriched GO terms in the BP category of upregulated genes included cell cycle (P=1.88×10^−29^), involving DEGs such as *AURKA, CCNA2, CCNE1, CDC20* and *CCNB2*, M phase (P=1.88×10^−29^) associated with a number of DEGs, including *AURKA, CCNA2, CDC20* and *CCNB2*, and cell cycle phase (P=2.89×10^−28^) associated with DEGs such as *AURKA, CCNA2, CCNE1, CDC20* and *CCNB2* ([Table IV](#tIV-ol-0-0-7310){ref-type="table"}). A total of six pathways were significantly enriched for upregulated genes, including cell cycle (P=6.68×10^−11^; e.g., *CCNA2, CCNE1, CDC20* and *CCNB2*), oocyte meiosis (P=1.76×10^−7^; e.g., *AURKA, CCNE1, CDC20* and *CCNB2*), DNA replication (P=3.43×10^−4^; e.g., *RFC4* and *POLE2*) and p53 signaling pathway (P=4.28×10^−4^; e.g., *CCNE1* and *CCNB2*) ([Table V](#tV-ol-0-0-7310){ref-type="table"}). The five enriched Reactome pathways of upregulated genes included cell cycle, mitotic (P=3.93×10^−22^; e.g., *AURKA, CCNA2, CCNE1, CDC20, CCNB2, RRM2* and *KIF20A*), cell cycle checkpoints (P=6.55×10^−7^; e.g., *CCNE1, CDC20* and *CCNB2*), telomere maintenance (P=1.70×10^−6^; e.g., *HIST1H2AC, HIST2H2AA3* and *HIST1H2BD*), DNA replication (P=3.52×10^−4^; e.g., *RFC4* and *POLE2*) and metabolism of nucleotides (P=4.04×10^−3^; e.g., *TYMS* and *RRM2*) ([Table III](#tIII-ol-0-0-7310){ref-type="table"}).

### Analysis of transcription factors and genes associated with cancer

Transcription factor analysis of DEGs revealed that 21 transcription factors (e.g., *ARNT, FOXP1* and *HEY1*) were significantly downregulated in bladder cancer tissues and 8 transcription factors (e.g., *BCL3, EZH2* and *FOXM1*) were upregulated ([Table VI](#tVI-ol-0-0-7310){ref-type="table"}).

Analysis of screening for genes associated with bladder cancer identified that 2 proto-oncogenes, *DUSP26* and *MEIS1*, were downregulated and 12 proto-oncogenes (e.g., *AURKA, CCNA2* and *CCNE1*) were upregulated. Furthermore, 17 tumor suppressor genes (e.g., *ARHGEF12, BLCAP* and *CHD5*) were downregulated and 10 tumor suppressor genes (e.g., *BLM, CHEK1* and *CST6*) were upregulated ([Table VI](#tVI-ol-0-0-7310){ref-type="table"}).

### PPI network and PPI sub-network analysis

A PPI network of DEGs was constructed ([Fig. 1](#f1-ol-0-0-7310){ref-type="fig"}). The top five genes/proteins with the highest degree in the PPI network were *CCNA2, BUB1, CDC20, CCNB1* and *MAD2L1*, with degrees of 57, 53, 52, 50 and 44, respectively.

The obtained core sub-network from the PPI network included 24 DEGs ([Fig. 2](#f2-ol-0-0-7310){ref-type="fig"}). The *CDC20* has the highest degree (degree, 18). A number of DEGs exhibited degrees \>10, including *CCNA2* (degree, 17), *KIF11* (degree, 16), *AURKA* (degree, 15), *NUSAP1* (degree, 15) and *CCNB2* (degree, 14). Furthermore, *CDC20, CCNA2, CCNB2* and *AURKA* interacted with each other.

KEGG pathway enrichment analysis of the genes in the core sub-network revealed that DEGs were significantly involved in cell cycle (P=2.26×10^−5^; *CCNB2, PLK1, CDC20, CCNA2* and *MCM6*), oocyte meiosis (P=5.10×10^−4^; *CCNB2, PLK1, CDC20* and *AURKA*) and progesterone-mediated oocyte maturation (P=7.41×10^−3^; *CCNB2, PLK1* and *CCNA2*; [Table VII](#tVII-ol-0-0-7310){ref-type="table"}).

Discussion
==========

In the present study, gene expression profiling was used to investigate the molecular mechanisms underlying bladder cancer. A set of 335 upregulated and 420 downregulated DEGs were identified between bladder cancer samples and normal controls. Analysis of the PPI sub-network demonstrated that 24 DEGs were obtained, and *CDC20, CCNA2, CCNB2* and *AURKA* had \>10 degrees and interacted with each other. The pathway enrichment analysis revealed that these four genes were enriched in the cell cycle signaling pathway.

*CDC20* serves a key role in the spindle assembly checkpoint and is necessary for anaphase onset and cell cycle progression ([@b21-ol-0-0-7310]). The abnormal expression of spindle assembly checkpoint proteins during mitosis, including *CDC20*, is associated with chromosome aneuploidy, and results in poor differentiation, tumor aneuploidy and poor prognosis ([@b22-ol-0-0-7310]). Kidokoro *et al* ([@b23-ol-0-0-7310]) demonstrated that p53 inhibits tumor cell growth by indirectly regulating the expression levels of *CDC20*.

*CCNA2* and *CCNB2* encode cyclin and function as regulators of CDKs. In the present study, *CCNA2* was identified as an upregulated proto-oncogene. Lu *et al* ([@b24-ol-0-0-7310]) and Lee *et al* ([@b25-ol-0-0-7310]) have demonstrated that *CCNA2* is upregulated in bladder cancer. Increased expression of *CCNA2* has been associated with poor prognosis for individuals with bladder cancer ([@b26-ol-0-0-7310]). Furthermore, in the present study, the KEGG pathway enrichment analysis identified that *CCNB2* was enriched in the p53 signaling pathway. It has been demonstrated that the expression level of *CCNB2* is upregulated in bladder tumors during interphase and proteolysis ([@b24-ol-0-0-7310]), which is consistent with the results of the present study. Additionally, deletion of p53 in bladder epithelium has been demonstrated to lead to invasive cancer in a novel mouse model ([@b27-ol-0-0-7310]), indicating a key role for p53 in bladder cancer. Therefore, *CDC20, CCNA2* and *CCNB2* may contribute to the development of bladder cancer.

*AURKA*, another upregulated proto-oncogene identified in the present study, encodes a cell cycle-regulated kinase ([@b28-ol-0-0-7310]). A previous study identified *AURKA* to be a biomarker for the detection of bladder cancer, due to *AURKA* aneuploidy resulting in chromosomal loss or gain ([@b29-ol-0-0-7310]). Genomic instability, which may be caused by checkpoint loss and perturbation of cell cycle control, results in the development of bladder cancer ([@b30-ol-0-0-7310]). A recent study demonstrated that *AURKA* is associated with the presence and grade of urothelial bladder cancer, suggesting a potential role as a diagnostic and prognostic biomarker ([@b31-ol-0-0-7310]). Hence, *AURKA* may serve a key role during the progression of bladder cancer.

However, the present study has a number of limitations. For example, the results of the present study were only predicted by bioinformatical analysis and must be further confirmed by experimental test. The studies should also be conducted using a larger sample sizes. These limitations are to be addressed in a further study.

To conclude, the present study identified 420 downregulated and 335 upregulated DEGs. A number of important DEGs, including *CDC20, CCNA2, CCNB2* and *AURKA*, may serve pivotal roles in the development of bladder cancer by regulating the cell cycle, as well as mutual interactions. These results provide a theoretical basis for a subsequent experimental study, and may contribute to an improved understanding of the molecular mechanisms that underlie bladder cancer.
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###### 

Top 10 enriched GO terms in the Biological Process category for downregulated differentially expressed genes in bladder cancer.

  Term                                                   n     P-value       Example genes
  ------------------------------------------------------ ----- ------------- ------------------------------------------
  GO: 0006936 \~ muscle contraction                      14    3.60×10^−5^   *CRYAB, TACR2, MYH3, CALD1, VIPR1*...
  GO: 0003012 \~ muscle system process                   14    9.48×10^−5^   *CRYAB, TACR2, MYH3, CALD1, VIPR1*...
  GO: 0030029 \~ actin filament-based process            16    3.19×10^−4^   *DLC1, MYH3, CALD1, NF1, FLNA*...
  GO: 0001656 \~ metanephros development                   7   3.93×10^−4^   *TCF21, BDNF, ITGA8, BCL2, HOXA11*...
  GO: 0040012 \~ regulation of locomotion                13    1.21×10^−3^   *RTN4, DLC1, PRKCA, NF1, SMAD3*...
  GO: 0030334 \~ regulation of cell migration            12    1.38×10^−3^   *RTN4, DLC1, LAMA3, BCL2, NF1*...
  GO: 0030336 \~ negative regulation of cell migration     7   1.59×10^−3^   *DLC1, BCL2, NF1, ILK, TGFBR3*...
  GO: 0030036 \~ actin cytoskeleton organization         14    1.62×10^−3^   *DLC1, CALD1, NF1, FLNA, CORO2B*...
  GO: 0060284 \~ regulation of cell development          13    2.10×10^−3^   *RTN4, NTF3, HOXA11, NF1, NLGN1*...
  GO: 0045449 \~ regulation of transcription             79    2.24×10^−3^   *ZNF383, LCOR, MAP3K13, RNF20, KCNH4*...

GO, gene ontology.

###### 

The two enriched Kyoto Encyclopedia of Genes and Genomes pathways for downregulated differentially expressed genes in bladder cancer.

  Term                       n     P-value       Genes
  -------------------------- ----- ------------- ------------------------------------------------------------------------------
  hsa04510: Focal adhesion   12    3.86×10^−3^   *PRKCA, LAMA3, ITGA8, BCL2, ILK, LAMC1, LAMB1, FLNC, FLNA, PARVA, VCL, MYL9*
  hsa04530: Tight junction     9   8.10×10^−3^   *PRKCA, GNAI1, MYH3, CNKSR3, MYH11, MYH14, CLDN11, TJAP1, MYL9*

hsa, *homo sapiens*.

###### 

Enriched Reactome pathways for downregulated and upregulated differentially expressed genes in bladder cancer.

  Term                                      n     P-value        Example genes
  ----------------------------------------- ----- -------------- ----------------------------------------------------
  Downregulated                                                  
    REACT_17044: Muscle contraction           5   2.46×10^−3^    *TNNT3, DES, MYH3, DMD, TPM2*
  Upregulated                                                    
    REACT_152: Cell cycle, mitotic          49    3.93×10^−22^   *CDC20, CCNB2, KIF23, E2F2, AURKA*...
    REACT_1538: Cell cycle checkpoints      17    6.55×10^−7^    *CDC20, CCNB2, CHEK1, MCM2, UBE2C*...
    REACT_7970: Telomere maintenance        12    1.70×10^−6^    *HIST1H2AC, HIST2H2AA3, HIST1H2BD, H2BFS, RFC4*...
    REACT_383: DNA replication              12    3.52×10^−4^    *RFC4, POLE2, PSMC4, RFC2, PSMD10*...
    REACT_1698: Metabolism of nucleotides     9   4.04×10^−3^    *TYMS, RRM2, DTYMK, DCK, CAD*...

###### 

Top 10 enriched GO terms in Biological Process category for upregulated differentially expressed genes in bladder cancer.

  Term                                           n    P-value        Example genes
  ---------------------------------------------- ---- -------------- -------------------------------------------
  GO: 0007049 \~ cell cycle                      76   1.88×10^−29^   *CDC20, CCNB2, KIF23, E2F2, KIFC1*...
  GO: 0000279 \~ M phase                         52   1.88×10^−29^   *CDC20, CCNB2, KIF23, KIFC1, PRC1*...
  GO: 0022403 \~ cell cycle phase                56   2.89×10^−28^   *CDC20, CCNB2, KIF23, KIFC1, PKMYT1*...
  GO: 0022402 \~ cell cycle process              63   3.37×10^−27^   *CDC20, CCNB2, KIF23, TTK, AURKA*...
  GO: 0000278 \~ mitotic cell cycle              51   4.83×10^−26^   *CDC20, CCNB2, KIF23, KIFC1, TTK*...
  GO: 0000280 \~ nuclear division                40   7.79×10^−25^   *CDC20, CCNB2, KIF23, KIFC1, NEK2*...
  GO: 0007067 \~ mitosis                         40   7.79×10^−25^   *CDC20, CCNB2, KIF23, KIFC1, PKMYT1*...
  GO: 0000087 \~ M phase of mitotic cell cycle   40   1.56×10^−24^   *CDC20, CCNB2*, KIF23, *PKMYT1, AURKA*...
  GO: 0048285 \~ organelle fission               40   3.64×10^−24^   *CDC20, CCNB2, KIF23, PTTG1, CEP55*...
  GO: 0051301 \~ cell division                   42   6.70×10^−22^   *CDC20, CCNB2, KIF23, CKS1B, PRC1*...

GO, gene ontology.

###### 

The six enriched Kyoto Encyclopedia of Genes and Genomes pathways for upregulated differentially expressed genes in bladder cancer.

  Term                                                n     P-value        Example genes
  --------------------------------------------------- ----- -------------- --------------------------------------------------------
  hsa04110: Cell cycle                                21    6.68×10^−11^   *CDC20, CCNB2, E2F2, PKMYT1, TTK*...
  hsa04114: Oocyte meiosis                            16    1.76×10^−7^    *CDC20, CCNB2, SGOL1, PKMYT1, AURKA*...
  hsa03030: DNA replication                             7   3.43×10^−4^    *RFC4, POLE2, RFC2, MCM2, FEN1*...
  hsa04115: P53 signaling pathway                       9   4.28×10^−4^    *CCNB2, CCNE2, CCNB1, BID, CCNE1*...
  hsa04914: Progesterone-mediated oocyte maturation     9   2.05×10^−3^    *CCNB2, CCNB1, MAD2L1, PLK1, BUB1*...
  hsa05322: Systemic lupus erythematosus                9   4.93×10^−3^    *HIST1H2AC, HIST2H2AA3, CD86, HIST1H2BD, HIST1H2BK*...

hsa, *Homo sapiens*.

###### 

Transcription factors and genes associated with cancer in the differentially expressed genes in bladder cancer.

  Terms               Genes                                                                                                                                             n
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- -----
  TF genes                                                                                                                                                              
    Downregulated     *ARNT, FOXP1, HEY1, HOXA11, HOXA3, HOXA9, ISL1, LMO3, MEIS1, NR1H3, NR1H4, NR3C2, POU3F1, POU3F4, RORB, SMAD3, SP3, TCF21, YAF2, ZNF10, ZNF174*   21
    Upregulated       *BCL3, EZH2, FOXM1, IRF1, RELB, TCEB3, TFDP1, XBP1*                                                                                                 8
  Oncogenes                                                                                                                                                             
    Downregulated     *DUSP26, MEIS1*                                                                                                                                     2
    Upregulated       *AURKA, BCL3, CCNA2, CCNE1, CEP55, DCUN1D1, FGFR1OP, HMMR, MAP3K8, MYB, PTTG1, VEGFA*                                                             12
  Tumor suppressors                                                                                                                                                     
    Downregulated     *ARHGEF12, BLCAP, CHD5, DLC1, FOXP1, MFHAS1, NDRG4, NF1, PACRG, PEG3, SCARA3, SMAD3, TGFBR2, TGFBR3, VCL, YAP1, ZDHHC2*                           17
    Upregulated       *BLM, CHEK1, CST6, ERRFI1, IRF1, MT1G, PLEKHG2, RASSF1, SLC9A3R1, TNFAIP3*                                                                        10

TF, transcription factor.

###### 

Enriched Kyoto Encyclopedia of Genes and Genomes pathways for differentially expressed genes of protein-protein interaction sub-network.

  Term                                                n   P-value       Genes
  --------------------------------------------------- --- ------------- -----------------------------------
  hsa04110: Cell cycle                                5   2.26×10^−5^   *CCNB2, PLK1, CDC20, CCNA2, MCM6*
  hsa04114: Oocyte meiosis                            4   5.10×10^−4^   *CCNB2, PLK1, CDC20, AURKA*
  hsa04914: Progesterone-mediated oocyte maturation   3   7.41×10^−3^   *CCNB2, PLK1, CCNA2*

hsa, *homo sapiens*.
